Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F Chatal

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinomaM A Mahé, P Fumoleau, M Fabbro, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 21, 2007
Radiolabeling and targeting of lipidic nanocapsules for applications in radioimmunotherapyE Jestin, M Mougin-Degraef, A Faivre-Chauvet, et al.
Nuclear Medicine and Biology|August 1, 1993
Introduction of five potentially metabolizable linking groups between 111In-cyclohexyl EDTA derivatives and F(ab')2 fragments of anti-carcinoembryonic antigen antibody--I. A new reproducible synthetic methodJ F Gestin, A Faivre-Chauvet, R C Mease, et al.
Nuclear Medicine and Biology|August 1, 1993
Introduction of five potentially metabolizable linking groups between 111In-cyclohexyl EDTA derivatives and F(ab')2 fragments of anti-carcinoembryonic antigen antibody--II. Comparative pharmacokinetics and biodistribution in human colorectal carcinoma-bearing nude miceA Faivre-Chauvet, J F Gestin, R C Mease, et al.
Nuclear Medicine Communications|September 1, 1996
Pre-clinical and clinical studies of two new bifunctional chelating agents for immunoscintigraphy with 111In-anti-CEA monoclonal antibodyA Faivre-Chauvet, R C Mease, A Chetanneau, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 24, 2001
Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studiesJ F Gestin, A Loussouarn, M Bardiès, et al.
Annales De Genetique|January 1, 1997
Chromosome aberrations after radiotherapy in patients treated for non Hodgkin's lymphomaM A Mahé, M J André, E Moyon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 1999
Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograftF Kraeber-Bodéré, A Faibre-Chauvet, C Saï-Maurel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injectionsF Kraeber-Bodéré, A Faivre-Chauvet, C Saï-Maurel, et al.
The International Journal of Biological Markers|September 1, 1986
The joint Task Group on clinical utility of labelled antibodies of the Society of Nuclear Medicine Europa (SNME) and the European Nuclear Medicine Society (ENMS)G Buraggi, K E Britton, U Büll, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinomaM A Mahé, P Fumoleau, M Fabbro, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|March 21, 2007
Radiolabeling and targeting of lipidic nanocapsules for applications in radioimmunotherapyE Jestin, M Mougin-Degraef, A Faivre-Chauvet, et al.
Nuclear Medicine and Biology|August 1, 1993
Introduction of five potentially metabolizable linking groups between 111In-cyclohexyl EDTA derivatives and F(ab')2 fragments of anti-carcinoembryonic antigen antibody--I. A new reproducible synthetic methodJ F Gestin, A Faivre-Chauvet, R C Mease, et al.
Nuclear Medicine and Biology|August 1, 1993
Introduction of five potentially metabolizable linking groups between 111In-cyclohexyl EDTA derivatives and F(ab')2 fragments of anti-carcinoembryonic antigen antibody--II. Comparative pharmacokinetics and biodistribution in human colorectal carcinoma-bearing nude miceA Faivre-Chauvet, J F Gestin, R C Mease, et al.
Nuclear Medicine Communications|September 1, 1996
Pre-clinical and clinical studies of two new bifunctional chelating agents for immunoscintigraphy with 111In-anti-CEA monoclonal antibodyA Faivre-Chauvet, R C Mease, A Chetanneau, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 24, 2001
Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studiesJ F Gestin, A Loussouarn, M Bardiès, et al.
Annales De Genetique|January 1, 1997
Chromosome aberrations after radiotherapy in patients treated for non Hodgkin's lymphomaM A Mahé, M J André, E Moyon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 1999
Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograftF Kraeber-Bodéré, A Faibre-Chauvet, C Saï-Maurel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injectionsF Kraeber-Bodéré, A Faivre-Chauvet, C Saï-Maurel, et al.
The International Journal of Biological Markers|September 1, 1986
The joint Task Group on clinical utility of labelled antibodies of the Society of Nuclear Medicine Europa (SNME) and the European Nuclear Medicine Society (ENMS)G Buraggi, K E Britton, U Büll, et al.
Pageof 15